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In this issue ofNeuron, Kremeyer et al. describe a gain-of-functionmutation of TRPA1 that produces a painful
disorder, familial episodic pain syndrome. This discovery enlarges the list of ion channels that, whenmutated,
produce pain. The growing universe of ‘‘channelopathic pain’’ presents some interesting overarching
concepts and questions.When C.S. Lewis described pain as
‘‘God’s megaphone,’’ he was referring to
psychological pain. Physical pain,
however, commands attention when it is
present, and can be incapacitating. Pain
occurs frequently and can be long-lasting
and severe, for example, in association
with diabetic neuropathy, postherpetic
neuralgia, nerve injury, and traumatic
limb amputation. Pain in these disorders
is often unresponsive or only partially
responsive to existing pharmacother-
apies, so there is a pressing need for the
development of more effective pain medi-
cations. In this issue of Neuron, Kremeyer
et al. (2010) present a comprehensive
analysis that links a gain-of-function
mutation of TRPA1, a nonselective cation
channel that functions as a sensor of envi-
ronmental irritants, to a familial pain
syndrome. This important study extends
the universe of human ‘‘channelopathic’’
pain syndromes caused by ion channel
mutations beyond the now well-estab-
lished pain disorders associated with
mutations of SCN9A, the gene that
encodes voltage-gated sodium channel
NaV1.7.
As described by Kremeyer et al., a point
mutation in the S4 transmembrane
segment of TRPA1 produces a syndrome
characterized by bouts of severe upper
body pain, triggered by physical stress,
cold, or fasting. These observations sug-
gest that, for at least some painful disor-
ders, TRPA1 antagonists may be useful
as therapeutic agents, but they also raise
interesting questions. The striking topo-
graphic pattern of pain affecting the
arms and trunk is unusual and as enig-622 Neuron 66, June 10, 2010 ª2010 Elseviematic as the distal limb pain or lower
body pain seen with NaV1.7 channelopa-
thies described below. We do not yet
understand why, in these cases, a muta-
tion of an ion channel that is expressed
widely within primary sensory neurons
should produce a spatially restricted
pattern of pain. Possible explanations
include regional expression of the
mutated channel within sensory neurons
innervating the affected part of the body,
or a focal pattern of access to modulatory
subunits or activating ligands. Alterna-
tively, spatially differentiated patterns of
expression of other channels in sensory
neurons might modulate the response of
these cells to the presence of the mutant
channel. Different levels of expression of
NaV1.8 have been shown, for example,
to exert a powerful cell background effect
that strongly influences the impact of
NaV1.7 mutations on excitability in
different types of neurons (Rush et al.,
2006).
Discovery of this new syndrome
enlarges the universe of ion channel
mutations that can cause chronic somatic
pain (Table 1). Since 2004, several dozen
different mutations of sodium channel
NaV1.7 have been shown to cause three
distinct clinical syndromes in humans
(Dib-Hajj et al., 2010). Dominant gain-of-
function missense mutations in NaV1.7
cause inherited erythromelalgia (Yang
et al., 2004), which is characterized by
episodes of excruciating burning pain
and redness in the distal extremities, trig-
gered by mild warmth. In almost all cases,
these mutations shift activation in a hyper-
polarizing direction, slow deactivation,r Inc.and increase the channel’s response to
slow subthreshold depolarizations (Cum-
mins et al., 2004). A second syndrome,
called paroxysmal extreme pain disorder
(PEPD), is characterized by perirectal,
periocular, and perimandibular pain, trig-
gered by perineal stimulation, and is
caused by another set of dominant gain-
of-function mutations of NaV1.7, which
impair inactivation; as a result of the inac-
tivation defect, these mutant channels
produce an enhanced persistent current,
which in many cases is reduced by the
sodium channel blocker carbamazepine,
a result that explains the favorable
response of patients with PEPD to treat-
ment with this medication. Complement-
ing this duo of gain-of-function syn-
dromes, a recessive loss-of-function
syndrome, NaV1.7-related congenital
insensitivity to pain, has now also been
identified (Cox et al., 2006). In this
disorder, affected individuals lack func-
tional NaV1.7 channels and do not feel
pain, thus accruing painless fractures,
painless burns, etc.
Thus far, causative mutations of other
members of the TRP and sodium channel
families, including NaV1.8 and NaV1.9
(which, like NaV1.7, acts as a threshold
channel, amplifying small depolarizing
inputs), and of other types of channels,
have not been reported in patients with
chronic somatic pain. NaV1.8 and NaV1.9
are preferentially expressed within dorsal
root ganglion neurons, particularly noci-
ceptors, and it might have been expected
that mutations in these channels would
alter pain perception or produce chronic
pain. The absence of reports of mutations
Table 1. Channelopathic Pain Syndromes
Disorder Inheritance Channel Mutation Effects on Channel Clinical Phenotype
Inherited erythromelalgia (IEM) autosomal dominant NaV1.7 missense lower threshold
for activation; enhanced
response to subthreshold stimuli
attacks of burning
pain and redness
in distal extremities;
triggered by mild
warmth and exercise
Paroxysmal extreme
pain disorder (PEPD)
autosomal dominant NaV1.7 missense impaired inactivation;
enhanced persistent current
episodic lower
body, ocular,
and jaw pain
accompanied by flushing
and other autonomic abnormalities
Channelopathy associated
insensitivity to pain (CIP)
autosomal recessive NaV1.7 nonsense loss of function of NaV1.7 inability to sense pain
Familial episodic
pain syndrome (FEPS)
autosomal dominant TRPA1 missense enhanced inward
current on activation
episodic upper
body pain, triggered
by fasting, cold,
or stress
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Previewsof NaV1.8 and NaV1.9 linked to pain
syndromes could represent an ascertain-
ment bias, since families with inherited
pain syndromes are very rare; patients
with the known NaV1.7- and TRPA1-
related pain syndromes describe the pain
as excruciating, and pain of this severity
might interfere with reproductive behavior.
But it also might be speculated that muta-
tions of NaV1.8 and NaV1.9 are less likely
to produce pain. The voltage-dependence
of NaV1.8 is shifted 20–30 mV in a depola-
rizing direction relative to other sodium
channels. Thus, NaV1.8 requires more
depolarization to activate but is relatively
resistant to inactivation; once activated,
it contributes the majority of the inward
transmembrane current underlying the
rising phase of the action potential and
supports repetitive firing in response to
sustained depolarization (Renganathan
et al., 2001). The presence of wild-type
NaV1.8 can support firing at very high
frequencies within permissive cell back-
grounds (Waxman, 2006), and it is
possible that gain-of-function mutations
of NaV1.8 do not enhance the activity of
nociceptors because other sodium chan-
nels such as NaV1.7 set threshold in these
primary sensory neurons, with still other
conductances (such as potassium chan-
nels) or cell-specific modulation setting
upper limits on firing frequency. NaV1.9
has been shown to regulate nociceptor
excitability. However, this channel has
a substantial effect on excitability even
when present at 20%–40% of its normal
levels, and this effect reaches an asymp-tote at levels well below those seen in
primary sensory neurons (Herzog et al.,
2001), so that gain-of-function mutations
might not always result in a significant
increase in nociceptor threshold or firing
rate.
Whether mutations of other ion chan-
nels can produce chronic pain is not yet
clear. Nociceptors express multiple ion
channels, including some that are also
present within CNS neurons. A mutation
of sodium channel NaV1.3 (Holland et al.,
2008) that increases the persistent and
ramp currents produced by this channel
and induces hyperexcitability and sponta-
neous firing in hippocampal neurons
(Estacion et al., 2010) has been shown
to produce epilepsy. It is well-established
that NaV1.3 accumulates within neu-
romas, including painful human neuromas
(Black et al., 2008). It would be interesting,
in this regard, to know whether individuals
housing this gain-of-function NaV1.3
mutation have an increased propensity
to develop neuropathic pain following
nerve injury.
Finally, we are led to inquire as to
whether sporadic cases of chronic pain,
due to founder or de novo ion channel
mutations, or pain syndromes associated
with ion channel polymorphisms, are
present within our population but have
eluded detection. Several cases of
sporadic erythromelalgia due to de novo
mutations in SCN9A have been described
(Dib-Hajj et al., 2010). Whether other
mutations in NaV1.7, in other sodium or
TRP channels, or in other ion channels,Neuronwould be identified via DNA profiling of
larger numbers of patients with sporadic
pain syndromes is not yet clear. A poly-
morphism of SCN9A, which produces
the R1150W substitution in NaV1.7, is
present in more than 15% of control
Caucasian chromosomes and has been
shown to increase nociceptor excitability
(Estacion et al., 2009). This polymorphism
has now been linked in genome-wide
association studies to enhanced pain
sensitivity and an apparent increase in
pain associated with disorders such as
osteoarthritis, spinal root nerve injury,
and phantom pain after limb amputation
(Reimann et al., 2010). Other polymor-
phisms that alter pain perception, or the
likelihood of developing chronic pain in
various injury or disease states, are prob-
ably lurking within the human genome.
Neuroscientists have traditionally cate-
gorized pain as ‘‘nociceptive’’ (triggered
by the presence of a noxious stimulus),
‘‘neuropathic’’ (due to dysfunction of the
nervous system), or ‘‘inflammatory’’ (re-
sulting from aberrant inflammatory activa-
tion of nociceptors). An increasing
number of peripheral injuries have been
shown to trigger changes in channel
expression and excitability of neurons
along the pain-signaling pathway, raising
the question of whether most chronic
pain has a neuropathic component. The
discovery of a growing list of pain disor-
ders, produced by mutations of ion chan-
nels, indicates that some pain disorders
are driven by intrinsic gain-of-function
changes in ion channels, and adds66, June 10, 2010 ª2010 Elsevier Inc. 623
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Previewsprimary (as opposed to secondary or
acquired) channelopathies as causes of
pain. Thus at least a few pain disorders
can be considered to be ‘‘channelo-
pathic.’’ These disorders provide us with
important model diseases in humans.
The borders remain blurry, however, since
ion channel genes may contain polymor-
phisms such as the R1140W NaV1.7
substitution that are present in control
populations but render pain-signaling
neurons hyperexcitable, lowering pain
threshold and possibly enhancing the
effect of environmental or epigenetic
changes.
Irrespective of these nosologic consid-
erations, a growing list of channelopathies
is helping us to make a translational leap
in which we are beginning to unravel,
molecule by molecule, the drivers of
human pain. The list is still small, but
each addition points toward a potential
therapeutic target. Ultimately, this molec-624 Neuron 66, June 10, 2010 ª2010 Elsevieular dissection of human pain may enable
us to mute ‘‘God’s megaphone.’’REFERENCES
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Tight control of synapse formation ensures that neurons connect to appropriate targets. In this issue of
Neuron, Klassen et al. identify ARL-8 GTPase as a regulator of presynaptic assembly.Without ARL-8, presyn-
aptic material aggregates en route to its destination, suggesting that ARL-8 acts like a dispersant to prevent
premature synaptic assembly in the axon.Much attention has been paid to signals
that initiate synaptogenesis. Contact
between an axon and its proper target
causes the postsynaptic membrane to
accumulate receptors and scaffolding
and causes the presynaptic varicosity to
acquire an active zone and vesicle cluster
(Jin and Garner, 2008; Owald and Sigrist,
2009). But focusing on signals for synapse
building can overlook two equally impor-
tant aspects of synaptogenesis: the infra-
structure of the neuron that delivers thebuilding materials to their site of assembly
and the negative control mechanisms that
prevent synapses from assembling where
they should not. In this issue of Neuron,
Klassen et al. (2010) describe aC. elegans
mutant that highlights these aspects of
synaptogenesis and points to a mecha-
nism for restricting presynaptic speciali-
zations to their proper positions.
Presynaptic proteins are synthesized in
the soma and transported along axons by
specialized motors. The componentstravel in at least two classes of transport
vesicle. One contains the components of
synaptic vesicles and a second, often
called a piccolo/bassoon transport
vesicle, contains components of the
active zone (Jin and Garner, 2008; Owald
and Sigrist, 2009). These components are
delivered principally by the kinesin-3
motors, which are distinct from those
that support axon outgrowth and path-
finding (Pack-Chung et al., 2007). Disrup-
tion of this transport can prevent synapse
